ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

  • P-ISSN2233-4203
  • E-ISSN2093-8950
  • ESCI, SCOPUS, KCI

논문 상세

Home > 논문 상세
  • P-ISSN 2233-4203
  • E-ISSN 2093-8950

In Vitro Inhibitory Effect of Licoricidin on Human Cytochrome P450s

Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2014, v.5 no.3, pp.84-88
https://doi.org/10.5478/MSL.2014.5.3.84
Sunju Kim (Kyungpook National University)
Heungchan O (Kyungpook National University)
Jeong Ah Kim (Kyungpook National University)
Seung Ho Lee (Yeungnam University)
Sangkyu Lee (Kyungpook National University)
  • 다운로드 수
  • 조회수

Abstract

Licoricidin isolated from Glycyrrhiza uralensis is known to have anticancer, anti-nephritic, anti-Helicobacter pylori,and antibacterial effects. In this study, a cocktail probe assay and liquid chromatography-tandem mass spectrometry (LC-MS/MS) were used to investigate the modulating effect of licoricidin on cytochrome P450 (CYP) enzymes in human livermicrosomes. When licoricidin was incubated at 0-25 μM with CYP probes for 60 min at 37oC, it showed potent inhibitoryeffects on CYP2B6-catalyzed bupropion hydroxylation and CYP2C9-catalyzed diclofenac 4’-hydroxylation with half maximalinhibitory concentration (IC50) values of 3.4 and 4.0 μM, respectively. The inhibition mode of licoricidin was revealed as competitive,dose-dependent, and non-time-dependent, and following the pattern of Lineweaver-Burk plots. The inhibitory effect oflicoricidin has been confirmed in human recombinant cDNA-expressed CYP2B6 and 2C9 with IC50 values of 4.5 and 0.73 μM,respectively. In conclusion, this study has shown the potent inhibitory effect of licoricidin on CYP2B6 and CYP2C9 activitycould be important for predicting potential herb-drug interactions with substrates that mainly undergo CYP2B- and CYP2C9-mediated metabolism.

keywords
Licoricidin, LC-MRM, cytochrome P450, inhibition


참고문헌

1

Rendic, S.. (2002). . Drug Metab. Rev, 34, 83-.

2

Guengerich, F. P.. (1997). . J. Mol. Pharmacol, 51, 147-.

3

Spaggiari, D.. (2014). . J. Pharm. Biomed. Anal, , -.

4

Messier, C.. (2012). . Oral Dis, 18, 32-.

5

Park, S. Y.. (2010). . Br. J. Nutr, 104, 1272-.

6

Fukai, T.. (2002). . Life Sci, 71, 1449-.

7

Tanaka, Y.. (2001). . J. Nutr. Sci. Vitaminol, 47, 270-.

8

Fukai, T.. (2003). . Fitoterapia, 74, 720-.

9

La, V. D.. (2011). . J. Periodontol, 82, 122-.

10

Song, M.. (2013). . Food Chem. Toxicol, 59, 549-.

11

Mo, S. L.. (2009). . Curr. Drug Metab, 10, 730-.

12

Turpeinen, M.. (2006). . Curr. Drug Metab, 7, 705-.

13

Hirota, T.. (2013). . Drug Metab. Pharmacokinet, 28, 28-.

14

Steward, D. J.. (1997). . Pharmacogenetics, 7, 361-.

투고일Submission Date
2014-07-28
수정일Revised Date
2014-08-27
게재확정일Accepted Date
2014-08-28
상단으로 이동

Mass Spectrometry Letters